-
Vardenafil HCl Trihydrate: Assay Guide
2026-08-12
This scenario-based guide explains how Vardenafil HCl Trihydrate (SKU A4323) can support interpretable PDE5, cGMP, proliferation, and cytotoxicity experiments. It focuses on concentration logic, solvent compatibility, assay controls, proteoform-aware interpretation, and practical product-selection criteria.
-
Lassa Virus Spike: pH-Driven Entry and Inhibition
2026-08-12
The reference study maps how acidification reorganizes the Lassa virus spike before membrane fusion, identifying early transmembrane changes, pH-sensitive metal coordination, and later spike opening that promotes receptor release. Structural analysis combined with functional inhibition by ARN-75039 provides a mechanistic framework for understanding LASV entry and targeting related viral fusion processes.
-
Protease Inhibitor Cocktail for HepaRG Assays
2026-08-11
Learn how a Protease Inhibitor Cocktail can protect HepaRG-derived proteins without chelating divalent cations. This guide connects protease control to HBV/HDV assay design, differentiation state, and interpretation of biochemical endpoints.
-
Radioiodinated Balsalazide for UC Imaging in Mice
2026-08-11
Sanad et al. developed and evaluated radioiodinated balsalazide as a colon-directed tracer for ulcerative colitis in mice. The optimized chloramine-T labeling workflow produced a stable radiotracer and showed markedly elevated uptake in ulcerated colon, supporting its use for preclinical biodistribution and inflammatory bowel disease model studies.
-
OTUD3-SLC7A11 Drives Ferroptosis Resistance in ccRCC
2026-08-10
The 2025 Cancer Letters study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, lowers oxidative pressure, and enables clear cell renal cell carcinoma cells to resist sunitinib-induced ferroptosis. Its mechanistic framework links protein turnover to cystine metabolism and suggests that OTUD3–SLC7A11 activity may be a useful therapeutic and biomarker axis for studying tyrosine kinase inhibitor resistance.
-
ZNF263–ULK1 Autophagy Axis in ICC
2026-08-09
Yan and colleagues identify ZNF263 as a transcriptional driver of intrahepatic cholangiocarcinoma (ICC) proliferation and connect its activity to enhancer-mediated activation of ULK1 and autophagy. By combining clinical tissue analysis, genomic profiling, reporter validation, cellular assays, and xenograft experiments, the study provides a mechanistic framework for interpreting ZNF263 as a potential prognostic or therapeutic target.
-
L-Ornithine and the Liver–Brain Axis
2026-08-08
L-Ornithine is more than a urea cycle intermediate. Emerging evidence positions ornithine as a mechanistic bridge between hepatic OTC dysfunction, systemic nitrogen handling, astrocyte glycolysis, and CNS toxicity. This article outlines how translational researchers can use L-Ornithine to build more informative metabolic enzyme assays and liver–brain axis models.
-
Poly (I:C) Workflow for Innate Immune Assays
2026-08-07
Build reproducible interferon, dendritic-cell, and cardiomyocyte stress assays with Poly (I:C), a controllable dsRNA stimulus rather than a replicating pathogen. The workflow also shows how a 2024 cardiomyocyte study can guide route selection, controls, and interpretation of dsRNA-sensing experiments.
-
Bardoxolone Methyl: Precision Redox Modulation in Disease Mo
2026-08-07
Bardoxolone methyl (CDDO methyl ester) empowers researchers to precisely modulate the Nrf2 and NF-kB signaling pathways for advanced oxidative stress and inflammation studies. This guide details protocol enhancements, troubleshooting tactics, and translational insights drawn from recent breakthroughs in redox system biology, offering a practical edge for bench scientists.
-
Tunable Human Intestinal Organoids: Balancing Stemness and D
2026-08-06
This study introduces a human intestinal organoid system that achieves a controlled equilibrium between stem cell self-renewal and differentiation, overcoming previous limitations of cellular homogeneity and limited scalability. The optimized approach enables enhanced cell diversity and proliferative capacity, offering a robust platform for disease modeling and high-throughput applications.
-
Bay 11-7821 in Cancer Immunology: Mechanisms and Strategy
2026-08-06
Explore how Bay 11-7821 (BAY 11-7082) is revolutionizing translational research at the interface of inflammation, apoptosis, and immune modulation. This article offers mechanistic depth and practical strategy for deploying Bay 11-7821 in workflows addressing cancer immune resistance, with direct reference to recent breakthroughs in radiotherapy-immunotherapy synergy and advanced NF-κB pathway interrogation.
-
IGF2BP1-m6A-TUBB4B Axis Drives Hepatic Stellate Cell Activat
2026-08-05
This study identifies the m6A reader IGF2BP1 as a key regulator of hepatic stellate cell (HSC) activation, acting through stabilization of TUBB4B mRNA in an m6A-dependent manner. Targeting the IGF2BP1/TUBB4B/FAK axis emerges as a promising therapeutic strategy for liver fibrosis, with implications for advancing antifibrotic research.
-
GI 254023X: Unlocking ADAM10 Inhibition for Translational Im
2026-08-05
GI 254023X represents a new frontier in selective ADAM10 inhibition, bridging mechanistic insight into cell signaling, vascular integrity, and apoptosis with actionable strategies for translational researchers. This article synthesizes the molecular rationale, preclinical evidence, and workflow recommendations, while contextualizing GI 254023X’s unique advantages versus conventional protease inhibitors. Grounded in recent literature and referencing key advances, including the nuanced findings around synaptic modulation in amyloid-targeting approaches, this piece guides researchers toward robust, reproducible, and application-tailored use of GI 254023X.
-
TRIB3 Knockdown Enhances Sunitinib Sensitivity in ccRCC via
2026-08-04
This article examines a recent study demonstrating that TRIB3 knockdown sensitizes clear cell renal cell carcinoma (ccRCC) cells to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. The findings offer mechanistic insight into overcoming sunitinib resistance in ccRCC and suggest new avenues for therapeutic intervention.
-
Protease Inhibitor Cocktail EDTA-Free: Elevating Protein Int
2026-08-04
The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) by APExBIO empowers advanced protein extraction workflows by providing uncompromised protease inhibition without interfering with phosphorylation-sensitive downstream applications. Its broad-spectrum, EDTA-free formulation ensures compatibility with kinase assays and phosphoproteomics, making it a go-to choice for researchers demanding both versatility and precision.